Cassava Sciences Announces Positive Top-Line Clinical Results in Phase II Study Evaluating Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc. announced positive top-line Phase II results for simufilam, its oral drug candidate for Alzheimer’s disease dementia. The study enrolled over 200 patients with mild-to-moderate Alzheimer’s disease.